scispace - formally typeset
Open AccessPosted ContentDOI

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

TLDR
In this article , the neutralization of BNT162b2-vaccinated sera (collected at 1 month after dose 3) against the three Omicron sublineages was reported.
Abstract
Abstract The newly emerged Omicron SARS-CoV-2 has 3 distinct sublineages: BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected at 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralized USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses were 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s were 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

TL;DR: In this article , the neutralization of BA.1-infected sera against BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16.
Journal ArticleDOI

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

TL;DR: In this article , the neutralization of BA.1-infected sera against BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16.
Posted ContentDOI

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection

TL;DR: In this article , the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunized Omicron BA.1.1-infected individuals was reported.
Posted ContentDOI

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

TL;DR: In this article , the neutralization of BA.1-infected sera against BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2 was evaluated.
References
More filters
Journal ArticleDOI

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

TL;DR: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.529) variant in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines as mentioned in this paper .
Journal ArticleDOI

Spike mutation D614G alters SARS-CoV-2 fitness.

TL;DR: Hamsters infected with SARS-CoV-2 expressing spike D614G (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.
Journal ArticleDOI

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

TL;DR: The identification of the Omicron (B.1.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 20211 immediately caused concern owing to the number of alterations in the spike glycoprotein that could lead to antibody evasion as discussed by the authors .
Journal ArticleDOI

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.

TL;DR: In this paper, three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70 deletion + N 501Y+D614G from UK; and E484K from SA.
Journal ArticleDOI

An infectious cDNA clone of SARS-CoV-2

TL;DR: The reverse genetic system and reporter virus provide key reagents to study SARS-CoV-2 and develop countermeasures and were successfully used to evaluate the antiviral activities of interferon (IFN).
Related Papers (5)